


25X1

Approved For Release 2004/03/17 : CIA-RDP86T00608R000600200018-6

Approved For Release 2004/03/17 : CIA-RDP86T00608R000600200018-6

Top Secret





Daily Surveyor

25X1

Top Secret

25X



26 February 1975

25X1

Approved For Release 2004/03/17 : CIA-RDP86T00608R000600200018-6

Approved For Release 2004/03/17 : CIA-RDP86T00608R000600200018-6

SURVEYOR

25X1

OSI-S- 39/75

26 February 1975

This publication is produced daily from selected incoming reports of all kinds. The views expressed are preliminary and subject to change. They have not been coordinated outside of OSI and OWI and do not necessarily reflect official positions of these offices. No action should be taken based solely on the preliminary evaluations of items herein. Users should consult the original sources of items for greater details. Questions concerning this publication should be directed to the Surveyor Staff, OSI,

25X1

Soviet Use of Electrosleep (ES) Therapy Increases: S. R. Roytenburd, head of the Department of Electrosleep and Functional Diagnosis at the Polyclinic of the Moscow-Kursk Rail Sector has reported the use of ES therapy at 84 treatment centers in Moscow. ES therapy at the Polyclinic of the Moscow-Kursk Rail Sector lasts a month and consists of a 60-minute session each day.

25X1

Comment: The Soviets now have 84 institutes employing ES techniques; only 51 institutes were involved in 1969. This increase is indicative of heightened Soviet application of ES therapy.

25X1

Since the early 1950s, the Soviets have claimed success in using ES for a large variety of therapeutic purposes. Some of the types of patients thought by the Soviets to benefit from ES therapy include: insomniacs, those with some forms of depression and anxiety neurosis, patients with certain cardiovascular

25X1

25X1

Approved For Release 2004/03/17 : CIA-RDP86T00608R000600200018-6

illnesses, women who develop toxemias in early pregnancy, and children with neuropsychiatric diseases. Soviet ES studies, however, have not been controlled carefully so that a placebo effect cannot be ruled out.

25X1

25X1

25X1

Approved For Release 2004/03/17 : CIA-RDP86T00608R000600200018-6

OST S 39/75
26 Feb 75